Gilde Healthcare exits occupational health provider BlijWerkt to Mentha Capital - Gilde Healthcare

Gilde Healthcare exits occupational health provider BlijWerkt to Mentha Capital

December 18, 2019

Utrecht (the Netherlands) – Gilde Healthcare today announced it has sold its majority stake in occupational health provider BlijWerkt to Mentha Capital, subject to approval by the Dutch Healthcare Authority. Led by Gilde, BlijWerkt has become a national player and challenger to the established occupational health providers. The successful growth of the company is the result of a differentiating proactive approach and expansion through acquisitions.

BlijWerkt is a fast-growing occupation health provider. Supporting both large organizations and SMEs in managing absenteeism by improving the vitality of organizations and their employees. BlijWerkt manages the process of employee sick leave and return to work.

Gilde Healthcare played an active role in the expansion of the company through the acquisition and integration of other occupational health providers such as Metaplanning, Re-on, Tredin and Immediator. “Gilde Healthcare is well entrenched in the healthcare market and has actively supported our growth trajectory. In a few years we have grown from a local SME service provider to a national player with large clients in our portfolio,” says Ruud Pels, director of BlijWerkt.

Gilde Healthcare reflects positively on its collaboration with BlijWerkt: “as a sector specialist with an active growth strategy, we have been able to add a lot of value,” says Hugo de Bruin, partner at Gilde Healthcare, “by investing in quality of service and the expansion of BlijWerkt towards a national player, we have created an alternative to the large incumbents. This is beneficial for both employees and employers.”

After the acquisition, BlijWerkt will collaborate with the paraDIGMA group. “By joining forces, paraDIGMA and BlijWerkt can further improve the quality and service to its customers and lay a solid foundation for further growth,” said Barend Rutten, partner at Mentha Capital.

In the sale of BlijWerkt, Oaklins acted as the exclusive M&A advisor to the sellers and Jacoline Gortzak, Legaltree, as the legal advisor.

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing € 1 billion ($ 1.2 billion) across two fund strategies: private equity and venture & growth capital. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America.
www.gildehealthcare.com

About BlijWerkt

BlijWerkt is the health and safety service that combines the power of the bigger players with the flexibility and personal attention of smaller players. With 120 staff, we are known as a vibrant leader, energizing employers and employees alike.
www.blijwerkt.nl

About Mentha Capital

Mentha Capital is an independent investment company that focuses on the lower-end of the mid-market in the Benelux. Mentha invests in established, medium-sized and profitable companies that have the opportunity to grow further through a buy-and-build strategy, expansion into new markets or an organizational transition. With more than EUR 400 million under management, Mentha works actively with entrepreneurs to support their companies in realizing their ambitious growth plans.
www.menthacapital.com

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022